Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Our strategy
Focused medicines company powered by technology leadership in R&D,
world-class commercialization, global access and data science
Where to play | our focus
How to win | our five priorities
Our aspiration
Strengthen our core
therapeutic areas
Advance our leading
technology platforms
Embrace operational
excellence every day
Unleash the power
of our people
Innovation
power
Top 3 innovator
Returns
High 30s IM margin,
attractive ROIC1
Accelerate
our 4 priority
geographies
Transform
Sandoz
Deliver transformative
innovation
Go big on data
and digital
1. Return on invested capital
6 Investor Relations | Q4 2021 Results
Build trust
with society
Growth
Consistent above
peer median
average growth
ESG
Global leader
in material
ESG factors
NOVARTIS | Reimagining MedicineView entire presentation